Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Source:http://linkedlifedata.com/resource/pubmed/id/21483003
J. Clin. Oncol.
2011
May
20
29
15
1987-96
